OLD NEWS- DEC 2017-BUT RELEVANT TO YOUR COMMENTS ABURBE.
US Dermatologists Delighted with Sanofi/Regeneron's Dupixent, but Increased Familiarity and Experience with Pfizer's Eucrisa May be Breeding Contempt
According to a recent study conducted by Spherix Global Insights, US dermatologists (n=104) report significantly higher satisfaction with Dupixent than with any of the other approved agents for the treatment of atopic dermatitis, while Eucrisa garners the lowest satisfaction ratings.
Ann: Ethics Approval for Phase 2 Atopic Dermatitis Study Received, page-114
-
- There are more pages in this discussion • 84 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.005(1.41%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 36.0¢ | 34.0¢ | $843.9K | 2.414M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 76260 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 149185 | 4 |
View Market Depth
| Last trade - 16.10pm 27/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
